JAMP seeks to bring abuse of dominance case re: STELARA | Smart & Biggar
JAMP filed an application with the Competition Tribunal on July 26, 2024, seeking leave to bring an abuse of dominance case against Janssen relating to ustekinumab (Janssen’s STELARA). JAMP proposes to allege that its ustekinumab biosimilar (JAMTEKI) business, or alternatively its biosimilars business, has been significantly harmed by Janssen’s “gaming of the regulatory system and […]
JAMP seeks to bring abuse of dominance case re: STELARA | Smart & Biggar Read More »